In addition, ALO administration effectively inhibited the growth of H1299‐derived subcutaneous tumors without affecting VPS4A KO H1299‐derived subcutaneous tumors, confirming its therapeutic efficacy in inhibiting NSCLC tumor growth in vivo by targeting VPS4A. This evidence concerns the gene VPS4A and non-small cell lung carcinoma.